nach oben

Erschienen in:

04.10.2022 | Zertifizierte Fortbildung

Immunbedingte Toxizitäten behandeln

Nebenwirkungen bei uroonkologischen Krebserkrankungen

verfasst von: PD Dr. med. Severin Rodler, Dr. med. Alexander Tamalunas, Dr. med. Gerald B. Schulz, Maria Apfelbeck, Dr. med. Melanie Götz, Elena K. Berg, Prof. Dr. med. Christian G. Stief, Dr. med. Jozefina Casuscelli

Erschienen in: Uro-News | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Auszug

Immunbedingte Nebenwirkungen der Systhemtherapie mit Immuncheckpointinhibitoren sind nur selten höhergradig - dann jedoch teilweise mit letalen Folgen. Entscheidend ist, Nebenwirkungen früh als solche zu erkennen und zu behandeln. Für jedes Organ bedarf es dabei eines individuellen Therapiemanagements. …

Waldman AD et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol, 2020;20:651-68

Motzer RJ et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90

Powles T et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2020;383:1218-30

Conroy M. et al. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun 2022;13:392

Esfahani K et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 2020;27,Suppl.2:87-97

Haanen J et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29,Suppl.4:iv264-6

Chen DS et al. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10

Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64

Hodi FS et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363:711-23

10.

Rudd CE et al. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12-26

11.

Okazaki T et al. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-24

12.

Keir ME et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-95

13.

Iwai Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-7

14.

Chhabra N et al. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. J Med Toxicol 2021;17:411-24

15.

Wang DY et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:1721-8

16.

U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://go.sn.pub/JgM8UD; zugegriffen am 19.8.2022

17.

Wu Z et al. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. Eur Urol 2022;81:414-25

18.

Couey MA et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 2019;7:165

19.

Unger JM et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. J Clin Oncol 2022;40:1474-86

20.

McCulloch JA et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med 2022;28:545-56

21.

Haanen J et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28,Suppl.4:iv119-42

22.

Jing, Y et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun 2020;11:4946

23.

Singhal SM et al. A digital therapeutic for proactive monitoring of patients on immune checkpoint inhibitor therapy for early detection of immune-related adverse events. J Clin Oncol 2020;38;Suppl.5:101

24.

Bajaj G et al. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol 2017;6:58-66

25.

Paderi A et al. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:860

26.

Verzoni E et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 2019;7:99

27.

Kobayashi K et al. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. In Vivo 2020;34:2647-52

28.

Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005;14,Suppl.1:2-8

29.

Kadokawa, Y et al. Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study. Mol Clin Oncol 2021;14:65

30.

Bergqvist V et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunology, Immunotherapy 2017;66:581-92

31.

Brahmer JR et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68

32.

Abu-Sbeih H et al. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol 2019;37:2738-45

33.

Pollack MH et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018;29:250-5

34.

Simonaggio A et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol 2019;5:1310-7

35.

Li M et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 2020;126:5088-97

36.

Arbour KC et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:2872-8

37.

Dolladille, C et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol, 2020. 6(6): p. 865-871.

38.

Schadendorf D et al. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 2019;121:144-53

Titel: Immunbedingte Toxizitäten behandeln
Nebenwirkungen bei uroonkologischen Krebserkrankungen
verfasst von: PD Dr. med. Severin Rodler
Dr. med. Alexander Tamalunas
Dr. med. Gerald B. Schulz
Maria Apfelbeck
Dr. med. Melanie Götz
Elena K. Berg
Prof. Dr. med. Christian G. Stief
Dr. med. Jozefina Casuscelli
Publikationsdatum: 04.10.2022
Verlag: Springer Medizin
Erschienen in: Uro-News / Ausgabe 10/2022
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI: https://doi.org/10.1007/s00092-022-5501-1

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Immunbedingte Toxizitäten behandeln

Nebenwirkungen bei uroonkologischen Krebserkrankungen

Auszug

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Peyronie-Krankheit wohl genetisch mitbedingt

Verlauf von Affenpocken-Infektion verändert sich

Mit Stents gegen ED?

Auswirkungen von Krebs im Kindesalter

Wann treten Infektionen nach BCG-Instillation auf?

Phenylephrin bei Priapismus - was zählt?

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie